Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus HYDROCHLOROTHIAZIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus HYDROCHLOROTHIAZIDE INTENSOL.
HYDRO-D vs HYDROCHLOROTHIAZIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
25-100 mg orally once daily in the morning.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic